In addition, Mig6/EGFR as a predictor of EGFR activity or erlotinib resistance demonstrated a high degree of accuracy in head and neck, bladder and lung cancer cell lines, primary xenografts, and patient samples. Here, ERRFI1 is linked to lung cancer.